Skip to main content
ILSUNG IS CO., LTD. logo

ILSUNG IS CO., LTD. — Investor Relations & Filings

Ticker · 003120 ISIN · KR7003120003 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2020-11-05 Regulatory Filings
Country KR South Korea
Listing KO 003120

About ILSUNG IS CO., LTD.

https://www.ilsung.com/

ILSUNG IS CO., LTD. is a pharmaceutical company specializing in the development and manufacturing of therapeutic products. The company's core portfolio is focused on antibiotics, cardiovascular agents, anesthetics, and contrast media. It is actively expanding its research and development into new therapeutic areas, including treatments for gastrointestinal (GI), central nervous system (CNS), and other cardiovascular (CV) conditions.

Recent filings

Filing Released Lang Actions
불성실공시법인지정예고
Regulatory Filings Classification · 95% confidence The document is a formal notice from the Korea Exchange (KRX) regarding the designation of Il-Yang Pharmaceutical as an 'unfaithful disclosure corporation' due to a delayed disclosure of asset acquisition. This is a regulatory announcement concerning compliance and disclosure violations. Since it does not fit into specific categories like M&A, financial reports, or director dealings, it falls under the general regulatory filing category.
2020-11-05 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Ilsung Pharmaceuticals, covering the period from January 1, 2020, to June 30, 2020. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Il-Sung Pharmaceuticals. It details specific transactions (sales) of shares by individuals related to the company's major shareholders. This type of filing, which reports personal share transactions by insiders or major shareholders, is classified as 'Director's Dealing' (DIRS) in the provided schema.
2020-07-29 Korean
유형자산취득결정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory disclosure regarding the acquisition of tangible assets (land and buildings) by Il-Sung Pharmaceutical. It details the asset description, acquisition price, purpose, and board resolution date. This type of disclosure, which reports a significant corporate event or transaction that does not fit into specific categories like M&A or share issues, is classified as a general regulatory filing.
2020-06-25 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). It details the identity of the shareholder (Himalaya Capital Management LLC), the target company (Il-Sung Pharmaceutical), and the specific changes in share ownership. This falls under the category of 'Major Shareholding Notification'.
2020-06-05 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Ilsung Pharmaceuticals, covering the period from January 1, 2020, to March 31, 2020. It contains detailed financial statements, management discussion, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.